CpG Oligonucleotides as Cancer Vaccine Adjuvants

Hidekazu Shirota 1,†, Debra Tross 2,† and Dennis M. Klinman 2,*

1 Department of Clinical Oncology, Tohoku University Hospital, Sendai 980-8577, Japan; E-Mail: Shirota@idac.tohoku.ac.jp
2 Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA; E-Mail: Trossd@mail.nih.gov

† These authors contributed equally to this work.

* Author to whom correspondence should be addressed; E-Mail: klinmand@mail.nih.gov; Tel.: +1-301-228-4265; Fax: +1-302-118-4281.

Academic Editor: Mary Lenora (Nora) Disis

Received: 24 March 2015 / Accepted: 28 April 2015 / Published: 8 May 2015

Abstract: Adjuvants improve host responsiveness to co-delivered vaccines through a variety of mechanisms. Agents that trigger cells expressing Toll-like receptors (TLR) activate an innate immune response that enhances the induction of vaccine-specific immunity. When administered in combination with vaccines designed to prevent or slow tumor growth, TLR agonists have significantly improved the generation of cytotoxic T lymphocytes. Unfortunately, vaccines containing TLR agonists have rarely been able to eliminate large established tumors when administered systemically. To improve efficacy, attention has focused on delivering TLR agonists intra-tumorally with the intent of altering the tumor microenvironment. Agonists targeting TLRs 7/8 or 9 can reduce the frequency of Tregs while causing immunosuppressive MDSC in the tumor bed to differentiate into tumoricidal macrophages thereby enhancing tumor elimination. This work reviews pre-clinical and clinical studies concerning the utility of TLR 7/8/9 agonists as adjuvants for tumor vaccines.

Keywords: CpG; TLR; vaccine; cancer
1. Introduction

Adjuvants are immunological agents that function to enhance the magnitude, breadth, quality and/or longevity of specific immune responses generated against co-administered antigens (Ag). Adjuvants are also used to reduce the dose and frequency of immunizations required to achieve protective immunity. Historically, vaccines were produced from live attenuated or heated inactivated organisms. While not appreciated at the time, those original vaccines contained bacterial contaminants that served as adjuvants [1].

There are several ways in which an adjuvant can promote immunity including:

1. Stabilizing or entrapping the Ag to extend release and thus prolong immune stimulation;
2. Promoting an inflammatory response at the site of Ag deposition thereby attracting activated macrophages and dendritic cells to improve Ag uptake and presentation;
3. Presenting co-stimulatory signals to T and B cells to enhance induction of Ag-specific immunity.

There is considerable interest in identifying safer and more effective adjuvants to enhance the utility of novel vaccines targeting infectious pathogens, allergy and cancer.

In support of these goals, immunologists and microbiologists have sought to elucidate the mechanism(s) of action of adjuvants. Notable success was achieved in the discovery of Toll like receptors (TLRs) and their role in promoting innate and adaptive immune responses, leading to a Nobel prize for Drs. Hoffmann and Beutler in 2011 [2,3].

2. Background Information Concerning TLRs

TLRs are an important component of the host’s pathogen sensing mechanism [4,5]. TLRs are typically classified into two families based on their localization: TLRs 1, 2, and 4–6 are expressed on the cell surface and sense bacterial cell wall components whereas TLRs 3 and 7–9 are expressed in endosomes and sense viral or bacterial nucleic acids [6]. The molecular structures recognized by TLRs have been evolutionarily conserved, are expressed by a wide variety of infectious microorganisms, and are termed pathogen-associated molecular patterns (PAMPs) [4,5]. The innate immune response elicited by TLR activation is characterized by the production of pro-inflammatory cytokines, chemokines, type I interferons and anti-microbial peptides. This innate response promotes and modulates the adaptive immune system. A common result is the expansion of Ag specific B cells that produce high affinity antibodies and of cytotoxic T cells including long-lasting memory cells that protect against subsequent infection through enhanced cytotoxic function targeting the effector phase [7,8].

Although several TLRs utilize similar signaling pathways, there are reproducible differences in the cytokine profile and adaptive immune response each elicits. Understanding which elements of the immune response are best supported by which TLR ligands should enable the development of adjuvants specifically tailored to enhance desired vaccination outcomes.

3. CpG ODN and TLR9

TLR9 recognizes and is activated by CpG motifs (consisting of a central unmethylated CG dinucleotide embedded within specific flanking regions) present at high frequency in bacterial DNA [9,10]. TLR9 molecules differ between species, with the structure of human versus mouse TLR9...
varying by 24% [9]. There is also variation between species in terms of which cell types express TLR9. For example, the TLR9 receptor is present in rodent but not in primate macrophages and myeloid dendritic cells (DC). In humans, TLR9 is expressed primarily by plasmacytoid DC and B cells [11–14]. Reflecting their utility as vaccine adjuvants, B lymphocytes exposed to TLR9 agonists become more susceptible to activation by Ag [15–17] while TLR9 stimulated pDC produce type I interferons and more efficiently present Ag to T cells [18–20]. The signaling pathway triggered when CpG interacts with TLR9 proceeds through the recruitment of myeloid differentiation factor 88 (MyD88), IL-1R-associated kinase (IRAK), and tumor necrosis factor receptor-associated factor 6 (TRAF6) [5]. This signaling cascade subsequently leads to the activation of several mitogen-activated kinases (MAPK) and transcription factors (such as NF-kB and AP-1), culminating in the transcription of pro-inflammatory chemokines and cytokines [5].

In humans, four distinct classes of CpG ODN have been identified based on differences in structure and the nature of the immune response they induce. Although each class contains at least one motif composed of a central unmethylated CG dinucleotide plus flanking regions, they differ in structure and immunological activity. “K”-type ODNs (also referred to as “B” type) contain from one to five CpG motifs typically on a phosphorothioate backbone. This backbone enhances resistance to nuclease digestion and substantially prolongs in vivo half-life (30–60 min compared with 5–10 min for phosphodiester) [21]. K-type ODNs trigger pDC to mature and secrete IFNα but have no effect on B cells [22,24]. C-type ODNs resemble K-type in being composed entirely of phosphorothioate nucleotides but resemble D-type in containing palindromic CpG motifs that can form stem loop structures or dimers. This class of ODN stimulates B cells to secrete IL-6 and pDC to produce IFNα [25,26]. P-Class CpG ODN contains double palindromes that can form hairpins at their GC-rich 3’ ends as well as concatamerize due to the presence of the 5’ palindromes. These highly ordered structures are credited with inducing the strongest type I IFN production of any class of CpG ODN [27,28].

4. Effect of CpG ODN on Human pDC and B Cells

In humans, TLR9 is expressed primarily by B cells and plasmacytoid DC (pDC) [29]. By comparison, multiple cells of the myeloid lineage including conventional DCs, monocytes and macrophages express TLR9 and respond to CpG ODN in mice [30]. pDC contribute to the initiation of many immune responses: they promote the generation of protective immunity to viral infection via their rapid and massive production of type I IFNs that support the generation of strong CTL responses [31–33]. Human pDC express TLRs 7 and 9 whereas myeloid DC (mDC) recognize TLRs 2, 3, 4, 5, 6 and 8 [29]. These divergent patterns of TLR expression support the hypothesis that distinct DC subsets generate unique/tailored responses optimized for the elimination of different pathogens [34,35]. Thus, CpG ODN should be
particularly useful as adjuvants for vaccines targeting viral infections and cancer, both of which require the type of strong CTL response elicited by pDC activation [36,37].

TLR9 activation also induces human memory B cells to proliferate, undergo class switching to IgG2a and secrete antibodies in a T cell independent manner [38]. By comparison, naive human B cells express low levels of TLR9 and do not respond directly to CpG ODN [14]. Ag stimulation via the B cell receptor induces naive B cells to up-regulate TLR9 expression and acquire responsiveness to CpG DNA. The requirement that naive B cells interact with cognate Ag before acquiring responsiveness to CpG prevents polyclonal B cell activation and reduces the risk of autoimmunity [39]. This synergy between BCR ligation and CpG ODN stimulation was verified in studies using CpG-Ag complexes to enhance Ag-specific class switching in vivo and supports the use of CpG ODN as adjuvants for vaccines designed to induce strong humoral responses [39].

5. CpG ODN as Vaccine Adjuvants: Importance of CpG-Ag Co-Delivery

A number of preclinical (murine) studies examined the immunogenicity of CpG-adjuvanted vaccines. Most reported that CpG ODN enhanced both the humoral and cellular (Th1 cells and CTL) immune response elicited by vaccines against pathogens, allergens and/or tumors [40]. To optimize the efficiency of Ag presentation by DCs requires that they encounter CpG ODN in the presence of vaccine Ag. Co-delivery of ODN plus Ag to the same APC accelerates the induction, increases the maximal level and extends the duration of the induced immune response [41]. It also supports modulation of Ab isotype and increases the immunogenicity of weak Ags [42]. Examples include studies in which ovalbumin or the hepatitis B surface antigen vaccine were administered with CpG ODN in which co-delivery to the same site significantly enhanced humoral protective immunity [21,43,44].

Based on such findings, a number of delivery strategies were examined to optimize the co-delivery of CpG ODN plus Ag to the same APCs. These approaches included the preparation of CpG-Ag conjugates, co-encapsulation in liposomes or on biodegradable microparticles, and the use of multicomponent nanorods [40,45,46]. Murine studies show that conjugating CpG ODN directly to Ag can boost immunity by up to 100-fold over that induced by simply mixing CpG ODN with immunogen [47,48]. The mechanisms by which CpG ODN-Ag conjugates enhance immunogenicity include insuring that both Ag and TLR agonist are taken up by the same APC and improving such uptake via DNA-binding receptors on the APCs (the latter effect is independent of the nature of the ODN but requires physical conjugation of DNA to target antigen).

While early murine studies focused on administering CpG ODN with defined vaccine Ags, their ability to support immunity when combined with complex vaccines expressing multiple tumor Ags has also been examined. One such endeavor examined the effect of conjugating CpG ODN to apoptotic tumor cells [49]. Whole mouse tumor cells were used because they expressed all possible tumor-associated Ags, allowing the host’s immune system to select the most immunogenic determinant based on presentation in the context of self MHC. Apoptotic tumor cells alone lack a TLR signaling moiety and thus fail to trigger the innate immune system in support of tumor specific immunity. To overcome this limitation, CpG was conjugated directly to tumor cells. The resultant adjuvant/vaccine combination triggered the expansion of tumor-specific CTL in the periphery that reduced the growth of small tumors and prevented their metastatic spread in murine experiments [49].
There is concern that inclusion of CpG ODN may increase the risk of vaccine-induced autoimmunity. CpG ODN and immune complexes that contain nucleic acids interact with TLR9 to increase the production of type I IFNs. While IFNa and IFNb can induce/exacerbate autoimmune disease [50–53], whether CpG based adjuvants have such an effect remains controversial, having not been observed in clinical vaccine trials [40,54]. We conclude that when a vaccine against cancer capable of overcoming tolerance to tumor Ags is required, the benefit of including a strong adjuvant (such as CpG ODN) outweighs the potential risk.

6. Effect of CpG DNA on MDSC and Macrophages in the Tumor Microenvironment

The anti-tumor activity of CpG-adjuvanted tumor vaccines was initially examined by delivering the vaccines systemically (by i.m. or s.c. routes) [55]. In murine studies, CpG-adjuvanted vaccines were effective against small tumors (<300 mm³) but were unable to eliminate large established tumors (of the size typical present in humans when first diagnosed). Whether delivered to mice with large or small tumors, the CpG-adjuvanted vaccines continued to induce tumor-specific CTL that were readily detected in the peripheral circulation. The problem was that immunosuppressive leukocytes present in the microenvironment of large tumors down-regulated the activity of these CTL. To overcome this limitation, CpG ODN were injected directly into the tumor bed with the goal of activating intratumoral DCs and facilitating tumor Ag presentation in situ.

Unexpectedly, local delivery interfered with the function of tolerogenic cells in the tumor milieu. Intra-tumoral injection of CpG ODN reduced the number and suppressive activity of tumor infiltrating monocyte-derived suppressor cells (MDSC) [56]. This was true of both free and vaccine associated CpG ODN, and led to a re-interpretation of data from clinical trials in which CpG ODN were delivered intratumorally to treat skin tumors or lymphoma. For example, Hofmann et al. induced complete or partial tumor remission in half of all patients with basal cell carcinoma or melanoma by intra-tumoral CpG injection [57]. Molenkamp et al. showed that intratumoral CpG increased the frequency of tumor-specific CD8 T cells in half of patients with melanoma [58]. Brody et al. showed that intratumoral CpG administration combined with radiation therapy induced systemic tumor regression (including at untreated sites) and tumor-reactive CD8 T cells in patients with low-grade B-cell lymphoma [59]. Kim et al. showed intratumoral injection of CpG ODN combined with radiation induced the regression of distal tumors, significantly decreased the frequency of FoxP3+ regulatory T cells (Tregs) and increased the frequency of CD123+ pDC at the site of CpG administration in patients with lymphoma [60]. These strategies are referred to as “in situ tumor vaccination” as they do not require the use of a customized vaccine.

These findings are consistent with animal studies showing that local CpG ODN treatment increased the number of tumor infiltrating T and NK cells while decreasing the frequency and inhibitory activity of tumor resident MDSC. The monocytic MDSC studied in that work expressed TLR9 and exposure to CpG ODN (i) triggered their rapid production of Th1-type cytokines (including IL-6, IL-12 and TNFa); (ii) impaired their ability to secrete arginase 1 and nitric oxide (factors critical to their suppression of T cell activity) and (iii) induced them to differentiation into tumoricidal macrophages [56]. These results suggest the existence of additional mechanisms through which CpG ODN could promote tumor regression. Unfortunately, human mMDSC do not express TLR9 or respond to CpG ODN, limiting the clinical
applicability of the murine findings. However, we find that the suppressive activity of mMDSC isolated from cancer patients can be reversed by treatment with TLR 7/8 agonists which induce them to differentiate into tumoricidal M1-like macrophages in a manner very similar to CpG ODN in mice [61].

7. TLR 7 and TLR8 Agonists as Cancer Vaccine Adjuvants

TLR7 and TLR8 are closely related receptors. They have similar structures and trigger a similar signaling cascade but differ in their pattern of cellular expression and thus the array of cytokines they elicit. In humans, TLR7 receptors are present on B cells and pDC which when activated secrete IFNa. TLR8 receptors are prevalent on neutrophils, monocytes and mDC which when triggered secrete TNFa, IL-12 and MIP1a [62,63]. Most ligands that interact with TLR7 also bind to TLR8. These include synthetic imidazquinolines (such as resiquimod/R-848), and the natural ligand ssRNA containing GU-rich sequences. Imiquimod and the guanosine analogue loxoribine are considered selective for TLR7 [64–66]) and a new generation of TLR8 selective agents has been described [63].

8. Trials Utilizing TLR 7/8 Agonists

The utility of TLR 7/8 ligands as vaccine adjuvants was evaluated in pre-clinical studies. Smorlesi et al. used transgenic mice expressing the HER2/neu oncogene that spontaneously develop mammary tumors [67]. When immunized with a DNA vaccine plus imiquimod, the incidence and growth rate of breast tumors was reduced when compared to DNA vaccination alone. Ab titers in mice receiving the imiquimod adjuvanted vaccine were higher and biased towards IgG2a and the number of CD8 T cells producing IFNg was also increased [68]. Narusawa et al. evaluated imiquimod as an adjuvant when used in combination with GM-CSF plus a gene-transduced tumor vaccine (GVAX). This vaccine combination significantly reduced the rate of tumor growth while increasing the number of pDC [69]. It should be noted that neither of these studies examined the effect of TLR 7/8 adjuvanted vaccines on large established tumors, limiting the ability to draw conclusions concerning their utility under conditions similar to those found in patients with cancer.

The TLR7/8 agonists currently approved by the FDA are designed for topical administration and are used primarily to treat HPV-induced warts, lentigo maligna, actinic keratoses, and basal or squamous cell carcinoma [70–73]. Clinical studies therefore routinely relied on topical administration to evaluate TLR 7/8 ligand activity. In a trial of patients with prostate cancer characterized by rising PSA titers (indicative of tumor growth), a prostate-specific peptide vaccine was combined with one of several adjuvants or immunomodulatory treatments. Patients receiving topical imiquimod over the vaccine injection site had the best clinical outcome with the slowest rise in PSA when compared to other modalities (including GM-CSF, hyperthermia, and mucin-1-mRNA/protamine complex) [74].

The ability of imiquimod to act as a topical adjuvant was also evaluated in patients with melanoma. When administered in conjunction with a variety of melanoma specific peptides plus Flt3 ligand, imiquimod stimulated an increase in the frequency of peptide-specific CD8 T cells [75]. When used in combination with a vaccine containing the NY-ESO-1 cancer Ag, four out of nine patients with melanoma developed specific Abs while seven out of nine developed CD4 T cell responses. CD8 T cell responses were not enhanced in these subjects nor did disease progression correlate with the induction of the types of immunity observed [76]. In an effort to improve outcome, resiquimod was substituted for
imiquimod based on animal studies showing that this TLR 7/8 agonist was better at generating Ag specific CD8 T cells [77,78]. A clinical study of NY-ESO-1 immunized melanoma patients found that the addition of resiquimod improved CD8 T cell responses in 25% of patients. No change in Ab or CD4 T cells was observed nor was time to progression improved (interestingly CD8 T cell responders also expressed the TLR7 SNP rs179008) [79].

9. Trials Utilizing CpG ODN

Agonists targeting TLR9 have been studied more extensively than those against TLR7/8. CpG ODN showed activity in murine models as monotherapy, in combination with cancer vaccines, and when paired with other modalities including radiotherapy, cryotherapy and chemotherapy. Numerous preclinical studies showed that including CpG ODN increased CTL frequency and that this effect correlated with slower tumor progression. For example, the immunogenicity of DC-based tumor vaccines was improved by the addition of CpG ODN as characterized by a marked improvement in CD8 T cell activity [80]. Most such studies delivered the CpG adjuvanted vaccines before or shortly after challenge and thus targeted tumors that were relatively small [81–86]. However, recent studies indicate that CpG ODN adjuvanted vaccines can eradicate even large established tumors. In one report, combining CpG ODN with a peptide vaccine targeting HPV16 E7 resulted in the elimination of tumors up to 250 mm³ in size. The growth of even larger tumors was significantly delayed although eradication was not achieved [87]. Eradication of very large tumors (1.2 cm in diameter) was observed in 50% of mice using a fusion protein vaccine targeting the E7 epitope in combination with CpG ODN plus a chemotherapeutic agent [88].

Several clinical trials examined the use of CpG ODN combined with peptide-based vaccines targeting tumor antigens. These studies commonly evaluated additional immunostimulatory agents such as Montanide ISA-51, GM-CSF and IFA. Phase I trials of the MART-1 peptide vaccine in patients with melanoma reported that the inclusion of CpG ODN increased the number of Ag-specific CD8 T cells by 10-fold [89,90]. Higher levels of IFNg, TNFa, and IL-2 were also detected [91]. In another trial using a multi-epitope peptide vaccine that included MART-1, gp100, and tyrosinase 40%–50% of patients developed IFNg secreting CD8 T cells and two-thirds of these had stable disease or partial regression. Unfortunately, these benefits lasted only 2–7 months and did not result in a significant difference in outcome when compared to other therapies in patients with stage IV or recurrent melanoma [92]. Expansion of CD8 T cells was also observed in studies utilizing the NY-ESO-1 peptide. In two trials, three out of three and nine out of 18 patients responded [93,94]. Elevated CD8 T cell responses were also observed against cancers expressing the NY-ESO-1 or LAGE-1 tumor Ag, and such responses were associated with improved clinical outcomes [95].

CpG ODN were also evaluated in combination with a vaccine targeting the Wilms’ Tumor-1 Ag (WT-1). Among patients receiving the CpG adjuvanted vaccine, 60% had stable disease compared to 15%–20% of those lacking the CpG component [96]. A study of patients with metastatic esophageal squamous cell carcinoma used a vaccine targeting the cancer-testis Ag peptides LY6K and TTK. Inclusion of CpG ODN led to an increase in CD8 T cells and secretion of IFNa. More patients receiving the CpG vaccine had stable disease compared to patients who did not (33% vs. 66%) although no complete or partial remissions were induced [97].
A reasonable conclusion from these human trials is that the addition of TLR adjuvants modestly boosts vaccine induced immunity but rarely results in tumor eradication. One explanation for this limited success is the ability of established tumors to evade immune elimination. The microenvironment in which tumors reside is rich in factors that support growth and contains Tregs and MDSCs that down-regulate tumor-specific immunity [98,99]. Tregs aid the host by suppressing autoreactive T cells and thus prevent autoimmunity [100–102]. However, when present in the tumor milieu they disrupt the host’s ability to destroy cancer cells [100,103,104]. Many tumors actively secrete factors such as CCL2 that recruit Tregs or that induce naive T cells to differentiate into Tregs [105–107]. Myeloid-derived suppressor cells are also present at high frequency in established tumors. They inhibit the tumoricidal activity of T and NK cells by interfering with l-arginine metabolism through the production of Arg-1 and iNOS or ROS [108,109]. Tregs and MDSC within the tumor microenvironment thus block the effector function of immune cells generated by TLR adjuvanted vaccines [110,111].

One way to limit the activity of these immunosuppressive cells is to induce their differentiation. For example, TGFβ, IL-10 and other factors can induce Tregs to differentiate while IL-6, IL-10 and TNFa can drive MDSC to differentiate into macrophages [100,112–114]. Intratumoral delivery of CpG ODN has been shown to slow tumor growth by altering the balance between suppression and immunity. While TLR9 stimulation increases systemic production of NK and CD8 T cells [55,115–117], local delivery improves tumor infiltration by such cells. Moreover, murine studies show that local delivery reduces the frequency of immunosuppressive Tregs and monocytic MDSCs in the tumor microenvironment [55,115–117]. In vitro studies demonstrate that MDSCs lose their immunosuppressive activity when treated with CpG DNA in association with reduced expression of NO and Arg-1 [56,118,119]. These effects were driven by the differentiation of mMDSC into tumoricidal M1 macrophages (as characterized by decreased expression of Ly6c and Gr-1 and increased expression of F4/80). Transferring these differentiated cells into tumor-bearing animals significantly slowed tumor growth, indicating that intra-tumoral delivery of CpG ODN (alone or in conjunction with vaccine) might profoundly alter the balance between tumoricidal and immunosuppressive cells [118,119].

Recent reports suggest that TLR 7/8 agonists also trigger MDSC maturation. Resquimod induces murine MDSC to differentiate into F4/80+ macrophages and CD11c+/I-Ad+ dendritic cells that support the expansion of CD4 and CD8 T cells [120]. Our group found that mMDSCs isolated from the peripheral blood of normal volunteers and cancer patients differentiated into M1-like macrophages when exposed to several TLR7 and TLR8 agonists. Interestingly, this was not a universal effect of all TLR agonists. PAM3, a ligand for TLR1/2, causes mMDSC to differentiate into M2-like macrophages that support tumor growth [61]. TLR7 agonists have additional effects on immune cells. For example, loxorurbin can inhibit tumor growth by promoting CD4 T cell proliferation and modulating the suppressive activity of Tregs [121].

10. TLR Agonist Combinations

Many strategies have been identified that enable the immune system to eliminate small tumors in animal models (including the intra-tumoral delivery of TLR agonists). Such strategies become increasingly less effective as larger cancers are targeted, in part because large tumors are infiltrated by immunosuppressive cells that inhibit the activity of tumoricidal CLT and NK cells [113,122,123].
Our group examined the effect of combining a novel TLR7/8 agonist (3M-052) with CpG ODN. While each TLR agonist alone slowed tumor growth, neither prevented the eventual outgrowth of established CT26 cancers. In contrast, the combination of both agonists cleared large established tumors in 87% of mice [119]. Mechanistically, this combination of TLR agonists reduced the number of mMDSCs and increased the number of CD8 T cells much more effectively than either agent alone. Intra-tumoral delivery of this TLR agonist combination up-regulated the expression of IL12, IFNg and granzyme B while lowering levels of Arg-1, Nos 2, CTLA-4 and TGFb [119]. The effect of combining TLR7 plus TLR9 agonists was evaluated in a single clinical trial. A virus-like nanoparticle containing CpG ODN plus the melanoma protein MelQbG10 was used in conjunction with imiquimod. The MelQbG10/CpG vaccine elicited tumor specific CD8 T cell responses. Inclusion of the TLR7 agonists significantly increased the magnitude of that response and improved the generation of memory T cells [124].

TLRs 7, 8 and 9 are all endosomal receptors, are expressed on overlapping cell types, and utilize similar signaling pathways [62,63,125]. What then accounts for their synergistic anti-tumor activity (particularly since TLR7 triggering may inhibit cytokine secretion induced by TLR9 agonists) [126,127]? A recent report shows that the expression of receptors by individual cells is stochastic and that cells with high levels of one receptor can have much lower levels of another [128]. We postulate that a greater fraction of APCs are activated by the combination of TLR7 plus TLR9 agonists than by either alone. Consistent with such a conclusion, the fraction of MDSC activated to differentiate and secrete cytokines was significantly increased when these cells were stimulated with both agonists vs. either one singly [119].

First generation TLR7/8 agonists were short acting agents designed for topical use. A new generation designed for in vivo administration and use as vaccine adjuvants is now available. Preliminary studies indicate that they are safe and persist at the injection site [63]. Delivering these agents in combination with CpG ODN into the tumor microenvironment as adjuvants for tumor vaccines thus represents a promising approach to the immunotherapy of large established cancers.

11. Conclusions

TLR agonists have complex and pleiotropic effects on the immune system. When used as adjuvants, TLR agonists boost Ag-specific cellular and humoral immunity. Stimulating endosomal TLRs is particularly effective at promoting the generation of CTL capable of eliminating viral pathogens and cancer. Simultaneous activation of multiple TLRs further improves the breadth and efficacy of such responses. When targeting cancer, intra-tumoral delivery of agonists against TLRs 7, 8 and 9 provides the added benefit of altering the tumor microenvironment. Such treatment reduces the frequency of immunosuppressive Tregs, MDSC and M2 macrophages while increasing the frequency of tumoricidal M1 macrophage. We believe that intra-tumoral delivery of vaccines that include TLR agonists should be of considerable benefit in the immunotherapy of cancer.

Author Contributions

Hidekazu Shirota drafted sections 1–6. Debra Tross drafted sections 7–10. Dennis M. Klinman prepared section 11 and revised sections 1–10.
Conflicts of Interest

Members of Dr. Klinman’s lab have patents related to the use of CpG oligonucleotides, alone and in combination with other adjuvants and antigens. All rights to such patents have been assigned to the Federal Government.

References
1. Dresser, D.W. Effectiveness of lipid and lipidophilic substances as adjuvants. *Nature* 1961, 191, 1169–1171.
2. Lemaitre, B.; Nicolas, E.; Michaut, L.; Reichhart, J.M.; Hoffmann, J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in *Drosophila* adults. *Cell* 1996, 86, 973–983.
3. Poltorak, A.; He, X.; Smirnova, I.; Liu, M.-Y.; van Huffel, C.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. *Science* 1998, 282, 2085–2088.
4. Janeway, C.A., Jr.; Medzhitov, R. Innate immune recognition. *Annu. Rev. Immunol.* 2002, 20, 197–216.
5. Akira, S.; Takeda, K. Toll-like receptor signalling. *Nat. Rev. Immunol.* 2004, 4, 499–511.
6. Kawasaki, T.; Kawai, T. Toll-like receptor signaling pathways. *Front. Immunol.* 2014, doi:10.3389/fimmu.2014.00461.
7. Wille-Reece, U.; Flynn, B.J.; Lore, K.; Koup, R.A.; Miles, A.P.; Saul, A.; Kedl, R.M.; Mattapallil, J.J.; Weiss, W.R.; Roederer, M.; et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. *J. Exp. Med.* 2006, 203, 1249–1258.
8. Xiao, H.; Peng, Y.; Hong, Y.; Huang, L.; Guo, Z.S.; Bartlett, D.L.; Fu, N.; Munn, D.H.; Mellor, A.; He, Y. Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. *J. Immunol.* 2013, 190, 5866–5873.
9. Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, K.; et al. A Toll-like receptor recognizes bacterial DNA. *Nature* 2000, 408, 740–745.
10. Takeshita, F.; Suzuki, K.; Sasaki, S.; Ishii, N.; Klinman, D.M.; Ishii, K.J. Transcriptional regulation of the human TLR9 gene. *J. Immunol.* 2004, 173, 2552–2561.
11. Hornung, V.; Rothenfusser, S.; Britsch, S.; Krug, A.; Jahrsdörfer, B.; Giese, T.; Endres, S.; Hartmann, G. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. *J. Immunol.* 2002, 168, 4531–4537.
12. Suzuki, Y.; Wakita, D.; Chamoto, K.; Narita, Y.; Tsuji, T.; Takeshima, T.; Gyobu, H.; Kawarada, Y.; Kondo, S.; Akira, S.; et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. *Cancer Res.* 2004, 64, 8754–8760.
13. Kadowaki, N.; Ho, S.; Antonenko, S.; Malefyt, R.W.; Kastelein, R.A.; Bazan, F.; Liu, Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. *J. Exp. Med.* 2001, 194, 863–869.

14. Bernasconi, N.L.; Onai, N.; Lanzavecchia, A. A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. *Blood* 2003, 101, 4500–4504.

15. Bourke, E.; Bosisio, D.; Golay, J.; Polentarutti, N.; Mantovani, A. The toll-like receptor repertoire of human B lymphocytes: Inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. *Blood* 2003, 102, 956–963.

16. Browne, E.P. Regulation of B-cell responses by Toll-like receptors. *Immunology* 2012, 136, 370–379.

17. Dement-Brown, J.; Newton, C.S.; Ise, T.; Damdinsuren, B.; Nagata, S.; Tolnay, M. Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes. *J. Leukoc. Biol.* 2012, 91, 59–67.

18. Kumar, H.; Kawai, T.; Akira, S. Pathogen recognition by the innate immune system. *Int. Rev. Immunol.* 2011, 30, 16–34.

19. Banchereau, J.; Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. *Immunity* 2006, 25, 383–392.

20. Kaisho, T. Pathogen sensors and chemokine receptors in dendritic cell subsets. *Vaccine* 2012, 30, 7652–7657.

21. Mutwiri, G.K.; Nichani, A.K.; Babiuk, S.; Babiuk, L.A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. *J. Control. Release* 2004, 97, 1–17.

22. Verthelyi, D.; Ishii, K.J.; Gursel, M.; Takeshita, F.; Klinman, D.M. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. *J. Immunol.* 2001, 166, 2372–2377.

23. Hartmann, G.; Battiany, J.; Poeck, H.; Wagner, M.; Kerkmann, M.; Lubenow, N.; Rothenfusser, S.; Endres, S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. *Eur. J. Immunol.* 2003, 33, 1633–1641.

24. Krug, A.; Towarowski, A.; Britsch, S.; Rothenfusser, S.; Hornung, V.; Bals, R.; Giese, T.; Engelmann, H.; Endres, S.; Krieg, A.M.; *et al.* Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. *Eur. J. Immunol.* 2001, 31, 3026–3037.

25. Marshall, J.D.; Fearon, K.; Abbate, C.; Subramanian, S.; Yee, P.; Gregorio, J.; Coffman, R.L.; van Nest, G. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. *J. Leukoc. Biol.* 2003, 73, 781–92.

26. Vollmer, J.; Weeratna, R.; Payette, P.; Jurk, M.; Schetter, C.; Laucht, M.; Wader, T.; Tluk, S.; Liu, M.; Davis, H.L.; *et al.* Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. *Eur. J. Immunol.* 2004, 34, 251–262.

27. Vollmer, J.; Krieg, A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. *Adv. Drug Deliv. Rev.* 2009, 61, 195–204.

28. Samulowit, U.; Weber, M.; Weeratna, R.; Uhlmann, E.; Noll, B.; Krieg, A.M.; Vollmer, J. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. *Oligonucleotides* 2010, 20, 93–101.
29. Iwasaki, A.; Medzhitov, R. Toll-like receptor control of the adaptive immune responses. *Nat. Immunol.* **2004**, *5*, 987–995.

30. Bruno, L.; Seidl, T.; Lanzavecchia, A. Mouse pre-immunocytes as non-proliferating multipotent precursors of macrophages, interferon-producing cells, CD8alpha(+) and CD8alpha(−) dendritic cells. *Eur. J. Immunol.* **2001**, *31*, 3403–3412.

31. Colonna, M.; Trinchieri, G.; Liu, Y.J. Plasmacytoid dendritic cells in immunity. *Nat. Immunol.* **2004**, *5*, 1219–1226.

32. Tel, J.; Lambeck, A.J.; Cruz, L.J.; Tacken, P.J.; de Vries, I.J.; Figdor, C.G. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. *J. Immunol.* **2010**, *184*, 4276–4283.

33. Von, H.P. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes. *Immunol. Lett.* **1995**, *47*, 157–162.

34. Hemont, C.; Neel, A.; Haslan, M.; Braudeau, C.; Josien, R. Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. *J. Leukoc. Biol.* **2013**, *93*, 599–609.

35. Hochrein, H.; O’Keeffe, M.; Wagner, H. Human and mouse plasmacytoid dendritic cells. *Hum. Immunol.* **2002**, *63*, 1103–1110.

36. Wakita, D.; Chamoto, K.; Zhang, Y.; Narita, Y.; Noguchi, D.; Ohnishi, H.; Iguchi, T.; Sakai, T.; Ikeda, H.; Nishimura, T. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. *Int. Immunol.* **2006**, *18*, 425–434.

37. Guery, L.; Dubrot, J.; Lippens, C.; Brighouse, D.; Malinge, P.; Pot, C.; Reith, W.; Waldburger, J.M.; Hugues, S. Ag-presenting CpG-activated pDCs prime Th17 cells that induce tumor regression. *Cancer Res.* **2014**, *74*, 6430–6440.

38. Hartmann, G.; Weeratna, R.D.; Ballas, Z.K.; Payette, P.; Blackwell, S.; Suparto, I.; Rasmussen, W.L.; Waldschmidt, M.; Sajuthi, D.; Purcell, R.H.; *et al.* Delineation of a CpG phosphorothioate oligodeoxinucleotide for activating primate immune responses in vitro and in vivo. *J. Immunol.* **2000**, *164*, 1617–1624.

39. Eckl-Dorna, J.; Batista, F.D. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. *Blood* **2009**, *113*, 3969–3977.

40. Shirota, H.; Klinman, D.M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. *Expert Rev. Vaccines* **2014**, *13*, 299–312.

41. Klinman, D.M.; Klaschik, S.; Sato, T.; Tross, D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. *Adv. Drug Deliv. Rev.* **2009**, *61*, 248–255.

42. Klinman, D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. *Nat. Rev. Immunol.* **2004**, *4*, 249–258.

43. Cooper, C.L.; Davis, H.L.; Morris, M.L.; Efler, S.M.; al Adhami, M.; Krieg, A.M.; Cameron, D.W.; Heathcote, J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind phase I/II study. *J. Clin. Immunol.* **2004**, *24*, 693–701.

44. Maurer, T.; Heit, A.; Hochrein, H.; Ampenberger, F.; O’Keeffe, M.; Bauer, S.; Lipford, G.B.; Vabulas, R.M.; Wagner, H. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. *Eur. J. Immunol.* **2002**, *32*, 2356–2364.
Immune CpG lls by antigen +. Intratumoral injection of CpG oligonucleotides induces 58.

57. 56. 55. 54. 53. 52. 51. 50. 49. 48. 47. 46. 45. 44. 43. 42. 41. 40. 39. 38. 37. 36. 35. 34. 33. 32. 31. 30. 29. 28. 27. 26. 25. 24. 23. 22. 21. 20. 19. 18. 17. 16. 15. 14. 13. 12. 11. 10. 9. 8. 7. 6. 5. 4. 3. 2. 1. Vaccines Clin. PF Haanen, B.G.; Sluijter, B.J, metastatic melanoma. in intralesionally injected TLR9

Hofmann, M.A.; Ishii, K.J.; Klinman, D.M Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 2001, 167, 3324–3328.

Shirota, H.; Sano, K.; Kikuchi, T.; Tamura, G.; Shirato, K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 2000, 164, 5575–5582.

Cho, H.J.; Takabayashi, K.; Cheng, P.M.; Nguyen, M.D.; Corr, M.; Tuck, S.; Raz, E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 2000, 18, 509–514.

Shirota, H.; Klinman, D.M. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol. Immunother. 2011, 60, 659–669.

Henault, J.; Martinez, J.; Riggs, J.M.; Tian, J.; Mehta, P.; Clarke, L.; Sasai, M.; Latz, E.; Brinkmann, M.M.; Iwasaki, A.; et al. Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity 2012, 37, 986–997.

Di, D.J.; Zhang, R.; Stagg, L.J.; Gagea, M.; Zhuo, M.; Ladbury, J.E.; Cao, W. Binding with nucleic acids or glycosaminoglycans converts soluble protein oligomers to amyloid. J. Biol. Chem. 2012, 287, 736–747.

Summers, S.A.; Hoi, A.; Steinmetz, O.M.; O’Sullivan, K.M.; Ooi, J.D.; Odobasic, D.; Akira, S.; Kitching, A.R.; Holdsworth, S.R. TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J. Autoimmun. 2010, 35, 291–298.

Guerrier, T.; Youinou, P.; Pers, J.O.; Jamin, C. TLR9 drives the development of transitional B cells towards the marginal zone pathway and promotes autoimmunity. J. Autoimmun. 2012, 39, 173–179.

Qin, M.; Li, Y.; Yang, X.; Wu, H. Safety of Toll-like receptor 9 agonists: A systematic review and meta-analysis. Immunopharmacol. Immunotoxicol. 2014, 36, 251–260.

Baines, J.; Celis, E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin. Cancer Res. 2003, 9, 2693–2700.

Shirota, Y.; Shirota, H.; Klinman, D.M. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J. Immunol. 2012, 188, 1592–1599.

Hofmann, M.A.; Kors, C.; Audring, H.; Walden, P.; Sterry, W.; Trefzer, U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 2008, 31, 520–527.

Molenkamp, B.G.; Sluijter, B.J.; van Leeuwen, P.A.; Santegoets, S.J.; Meijer, S.; Wijnands, P.G.; Haanen, J.B.; van den Eertwegh, A.J.; Scheper, R.J.; de Gruijl, T.D. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin. Cancer Res. 2008, 14, 4532–4542.
59. Brody, J.D.; Ai, W.Z.; Czerwinski, D.K.; Torchia, J.A.; Levy, M.; Advani, R.H.; Kim, Y.H.; Hoppe, R.T.; Knox, S.J.; Shin, L.K.; et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phase I/II study. J. Clin. Oncol. 2010, 28, 4324–4332.

60. Kim, Y.H.; Gratzinger, D.; Harrison, C.; Brody, J.D.; Czerwinski, D.K.; Ai, W.Z.; Morales, A.; Abdulla, F.; Xing, L.; Navi, D.; et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: A phase 1/2 study. Blood 2012, 119, 355–363.

61. Wang, J.; shirota, Y.; Bayik, D.; Shirota, H.; Tross, D.; Gulley, J.L.; Wood, L.V.; Berzofsky, J.A.; Klinman, D.M. Effect of TLR agonists on the differentiation and function of human monocytic myeloid derived suppressor cells. J. Immunol. 2015, 194, 4215–4221.

62. Gorden, K.B.; Gorski, K.S.; Gibson, S.J.; Kedl, R.M.; Kieper, W.C.; Qiu, X.; Tomai, M.A.; Alkan, S.S.; Vasilakos, J.P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 2005, 174, 1259–1268.

63. Vasilakos, J.P.; Tomai, M.A. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev. Vaccines 2013, 12, 809–819.

64. Heil, F.; Hmad-Nejad, P.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Gellert, T.; Dietrich, H.; Lipford, G.; Takeda, K.; Akira, S.; et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 2003, 33, 2987–2997.

65. Hemmi, H.; Kaisho, T.; Takeuchi, O.; Sato, S.; Sanjo, H.; Hoshino, K.; Horiiuchi, T.; Tomizawa, H.; Takeda, K.; Akira, S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002, 3, 196–200.

66. Heil, F.; Hemmi, H.; Hochrein, H.; Ampenberger, F.; Kirschning, C.; Akira, S.; Lipford, G.; Wagner, H.; Bauer, S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303, 1526–1529.

67. Muller, W.J.; Sinn, E.; Pattengale, P.K.; Wallace, R.; Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54, 105–115.

68. Smorlesi, A.; Papalini, F.; Orlando, F.; Donnini, A.; Re, F.; Provinciaeli, M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther. 2005, 12, 1324–1332.

69. Narusawa, M.; Inoue, H.; Sakamoto, C.; Matsumura, Y.; Takahashi, A.; Inoue, T.; Watanabe, A.; Miyamoto, S.; Miura, Y.; Hijiwaka, Y.; et al. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells. Cancer Immunol. Res. 2014, 2, 568–580.

70. Beutner, K.R.; Spruance, S.L.; Hougham, A.J.; Fox, T.L.; Owens, M.L.; Douglas, J.M., Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J. Am. Acad. Dermatol. 1998, 38, 230–239.

71. Schulze, H.J.; Cribier, B.; Requena, L.; Reifenberger, J.; Ferrándiz, C.; Garcia Diez, A.; Tebbs, V.; McRae, S. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from a randomized vehicle-controlled phase III study in Europe. Br. J. Dermatol. 2005, 152, 939–947.

72. Lebwohl, M.; Dinehart, S.; Whiting, D.; Lee, P.K.; Tawfik, N.; Jorizzo, J.; Lee, J.H.; Fox, T.L. Imiquimod 5% cream for the treatment of actinic keratosis: Results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol. 2004, 50, 714–721.
Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 2002, 27, 571–577.

Feyerabend, S.; Stevanovic, S.; Gouttefangeas, C.; Wernet, D.; Hennenlotter, J.; Bedke, J.; Dietz, K.; Pascolo, S.; Kuczyk, M.; Rammensee, H.G.; et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009, 69, 917–927.

Shackleton, M.; Davis, I.D.; Hopkins, W.; Jackson, H.; Dimopoulos, N.; Tai, T.; Chen, Q.; Parente, P.; Jefford, M.; Masterman, K.A.; et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Available online: http://archive.cancerimmunity.org/v4p9/040710.html#top (accessed on 1 March 2015).

Adams, S.; O’Neill, D.W.; Nonaka, D.; Hardin, E.; Chiriboga, L.; Siu, K.; Cruz, C.M.; Angiulli, A.; Angiulli, F.; Ritter, E.; et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 2008, 181, 776–784.

Chang, B.A.; Cross, J.L.; Najjar, H.M.; Dutz, J.P. Topical resiquimod promotes priming of CTL to parenteral antigens. Vaccine 2009, 27, 5791–5799.

Thomensen, L.L.; Topley, P.; Daly, M.G.; Brett, S.J.; Tite, J.P. Imiquimod and resiquimod in a mouse model: Adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004, 22, 1799–1809.

Sabado, R.L.; Pavlick, A.; Gnajtic, S.; Cruz, C.M.; Vengco, I.; Hasan, F.; Spadaccia, M.; Darvishian, F.; Chiriboga, L.; Holman, R.M.; et al. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol. Res. 2015, 3, 278–287.

Heckelsmiller, K.; Beck, S.; Rall, K.; Sipos, B.; Schlamp, A.; Tuma, E.; Rothenfusser, S.; Endres, S.; Hartmann, G. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 2002, 32, 3235–3245.

Muraoka, D.; Kato, T.; Wang, L.; Maeda, Y.; Noguchi, T.; Harada, N.; Takeda, K.; Yagita, H.; Guillame, P.; Luescher, I.; et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J. Immunol. 2010, 185, 3768–3776.

Junqueira, C.; Guerrero, A.T.; Galvaö-Filho, B.; Andrade, W.A.; Salgado, A.P.; Cunha, T.M.; Ropert, C.; Campos, M.A.; Penido, M.L.; Mendonça-Prevatio, L.; et al. Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. PLOS ONE 2012, 7, e36245.

Sin, J.I.; Kim, H.; Ahn, E.; Jeon, Y.H.; Park, W.S.; Lee, S.Y.; Kwon, B. Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett. 2013, 330, 190–199.

Silva, A.; Mount, A.; Krstevska, K.; Pejoski, D.; Hardy, M.P.; Owczarek, C.; Scotney, P.; Maraskovsky, E.; Baz Morelli, A. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. J. Immunol. 2015, 194, 2199–2207.

Aurisicchio, L.; Peruzzi, D.; Conforti, A.; Dharmapuri, S.; Biondo, A.; Giampaoli, S.; Fridman, A.; Bagchi, A.; Winkelmann, C.T.; Gibson, R.; et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin. Cancer Res. 2009, 15, 1575–1584.
86. Jacobs, C.; Duewell, P.; Hecksmiller, K.; Wei, J.; Bauernfeind, F.; Ellermeier, J.; Kissner, U.; Bauer, C.A.; Dauer, M.; Eigler, A.; et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. *Int. J. Cancer* **2011**, *128*, 897–907.

87. Zwaveling, S.; Ferreira Mota, S.C.; Nouta, J.; Johnson, M.; Lipford, G.B.; Offringa, R.; van der Burg, S.H.; Melief, C.J. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. *J. Immunol.* **2002**, *169*, 350–358.

88. Mansilla, C.; Berraondo, P.; Durantez, M.; Martínez, M.; Casares, N.; Arribillaga, L.; Rudilla, F.; Fioravanti, J.; Lozano, T.; Villanueva, L.; et al. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. *Int. J. Cancer* **2012**, *131*, 641–651.

89. Speiser, D.E.; Schwarz, K.; Baumgaertner, P.; Manolova, V.; Devevre, E.; Sterry, W.; Walden, P.; Zippelius, A.; Conzett, K.B.; Senti, G.; et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. *J. Immunother.* **2010**, *33*, 848–858.

90. Speiser, D.E.; Lienard, D.; Rufer, N.; Rubio-Godoy, V.; Rimoldi, D.; Lejeune, F.; Krieg, A.M.; Cerottini, J.C.; Romero, P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. *J. Clin. Invest.* **2005**, *115*, 739–746.

91. Baumgaertner, P.; Jandus, C.; Rivals, J.P.; Derré, L.; Lövgren, T.; Baitsch, L.; Guillaume, P.; Luescher, I.F.; Berthod, G.; Matter, M.; et al. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. *Int. J. Cancer* **2012**, *130*, 2607–2617.

92. Tarhini, A.A.; Leng, S.; Moschos, S.J.; Yin, Y.; Sander, C.; Lin, Y.; Gooding, W.E.; Kirkwood, J.M. Safety and immunogenicity of vaccination with MART-1 (26–35, 27L), gp100 (209–217, 210M), and tyrosinase (368–376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. *J. Immunother.* **2012**, *35*, 359–366.

93. Fourcade, J.; Kudela, P.; Ndrade Filho, P.A.; Janjic, B.; Land, S.R.; Sander, C.; Krieg, A.; Donnenberg, A.; Shen, H.; Kirkwood, J.M.; et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. *J. Immunother.* **2008**, *31*, 781–791.

94. Valmori, D.; Souleimanian, N.E.; Tosello, V.; Bhardwaj, N.; Adams, S.; O’Neill, D.; Pavlick, A.; Escalon, J.B.; Cruz, C.M.; Angiulli, A.; et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 8947–8952.

95. Karbach, J.; Gnijatic, S.; Bender, A.; Neumann, A.; Weidmann, E.; Yuan, J.; Ferrara, C.A.; Hoffmann, E.; Old, L.J.; Altorki, N.K.; et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: Association with survival. *Int. J. Cancer* **2010**, *126*, 909–918.

96. Ohno, S.; Okuyama, R.; Aruga, A.; Sugiyama, H.; Yamamoto, M. Phase I trial of Wilms’ Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. *Anticancer Res.* **2012**, *32*, 2263–2269.

97. Iwahashi, M.; Katsuda, M.; Nakamori, M.; Nakamura, M.; Naka, T.; Ojima, T.; Iida, T.; Yamaue, H. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. *Cancer Sci.* **2010**, *101*, 2510–2517.
98. Zitvogel, L.; Tesniere, A.; Kroemer, G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. *Nat. Rev. Immunol.* **2006**, *6*, 715–727.

99. Muller, A.J.; Scherle, P.A. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. *Nat. Rev. Cancer* **2006**, *6*, 613–625.

100. Colombo, M.P.; Piconese, S. Regulatory-T-cell inhibition versus depletion: The right choice in cancer immunotherapy. *Nat. Rev. Cancer* **2007**, *7*, 880–887.

101. Kim, J.M.; Rasmussen, J.P.; Rudensky, A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat. Immunol.* **2007**, *8*, 191–197.

102. Sakaguchi, S. Regulatory T cells: Key controllers of immunologic self-tolerance. *Cell* **2000**, *101*, 455–458.

103. Alizadeh, D.; Larmonier, N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. *Cancer Res.* **2014**, *74*, 2663–2668.

104. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* **2011**, *144*, 646–674.

105. Centuori, S.M.; Trad, M.; LaCasse, C.J.; Alizadeh, D.; Larmonier, C.B.; Hanke, N.T.; Kartchner, J.; Janikashvili, N.; Bonnotte, B.; Larmonier, N.; et al. Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-beta-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. *J. Leukoc. Biol.* **2012**, *92*, 987–997.

106. Siveen, K.S.; Kuttan, G. Role of macrophages in tumour progression. *Immunol. Lett.* **2009**, *123*, 97–102.

107. Jordan, J.T.; Sun, W.; Hussain, S.F.; DeAngulo, G.; Prabhu, S.S.; Heimberger, A.B. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. *Cancer Immunol. Immunother.* **2008**, *57*, 123–131.

108. Bronte, V.; Zanovello, P. Regulation of immune responses by L-arginine metabolism. *Nat. Rev. Immunol.* **2005**, *5*, 641–654.

109. Rodriguez, P.C.; Ochoa, A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. *Immunol. Rev.* **2008**, *222*, 180–191.

110. Fernandez, A.; Oliver, L.; Alvarez, R.; Fernandez, L.E.; Lee, K.P.; Mesa, C. Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination. *Hum. Vaccin Immunother.* **2014**, *10*, 3251–3260.

111. Butt, A.Q.; Mills, K.H. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. *Oncogene* **2014**, *33*, 4623–4631.

112. Li, Q.; Pan, P.Y.; Gu, P.; Xu, D.; Chen, S.H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. *Cancer Res.* **2004**, *64*, 1130–1139.

113. Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Bronte, V. Coordinated regulation of myeloid cells by tumours. *Nat. Rev. Immunol.* **2012**, *12*, 253–268.

114. Sevkov, A.; Umanovsky, V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: Thick as thieves. *J. Cancer* **2013**, *4*, 3–11.

115. Kawarada, Y.; Ganss, R.; Garbi, N.; Sacher, T.; Arnold, B.; Hammerling, G.J. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. *J. Immunol.* **2001**, *167*, 5247–5253.
116. Heckelsmiller, K.; Rall, K.; Beck, S.; Schlamp, A.; Seiderer, J.; Jahrsdörfer, B.; Krug, A.; Rothenfusser, S.; Endres, S.; Hartmann, G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. *J. Immunol.* 2002, 169, 3892–3899.

117. Grauer, O.M.; Molling, J.W.; Bennink, E.; Toonen, L.W.; Sutmuller, R.P.; Nierkens, S.; Adema, G.J. TLR ligands in the local treatment of established intracerebral murine gliomas. *J. Immunol.* 2008, 181, 6720–6729.

118. Shirota, H.; Klinman, D.M. Effect of CpG ODN on monocytic myeloid derived suppressor cells. *Oncoimmunology* 2012, 1, 780–782.

119. Zhao, B.G.; Vasilakos, J.P.; Tross, D.; Smirnov, D.; Klinman, D.M. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. *J. Immunother. Cancer* 2014, doi:10.1186/2051-1426-2-12.

120. Lee, M.; Park, C.S.; Lee, Y.R.; Im, S.A.; Song, S.; Lee, C.K. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. *Arch. Pharm. Res.* 2014, 37, 1234–1240.

121. Wang, C.; Zhou, Q.; Wang, X.; Wu, X.; Chen, X.; Li, J.; Zhu, Z.; Liu, B.; Su, L. The TLR7 agonist induces tumor regression both by promoting CD4+ T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells. *Oncotarget* 2015, 6, 1779–1789.

122. Gabrilovich, D.I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat. Rev. Immunol.* 2009, 9, 162–174.

123. Jiang, J.; Guo, W.; Liang, X. Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. *Hum. Immunol.* 2014, 75, 1128–1137.

124. Goldinger, S.M.; Dummer, R.; Baumgaertner, P.; Mihic-Probst, D.; Schwarz, K.; Hammann-Haenni, A.; Willers, J.; Geldhof, C.; Prior, J.O.; Kündig, T.M.; *et al.* Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. *Eur. J. Immunol.* 2012, 42, 3049–3061.

125. Trinchieri, G.; Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. *Nat. Rev. Immunol.* 2007, 7, 179–190.

126. Rosenberger, K.; Derkow, K.; Dembny, P.; Kruger, C.; Schott, E.; Lehnardt, S. The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration. *J. Neuroinflamm.* 2014, doi:10.1186/s12974-014-0166-7.

127. Berghofer, B.; Haley, G.; Frommer, T.; Bein, G.; Hackstein, H. Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production. *J. Immunol.* 2007, 178, 4072–4079.

128. Deng, Q.; Ramskold, D.; Reinius, B.; Sandberg, R. Single-cell RNA-seq reveals dynamic, random monoallelic gene expression in mammalian cells. *Science* 2014, 343, 193–196.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).